News & Updates

Oseltamivir appears to have similar efficacy as peramivir in the treatment of young children with severe influenza B, a study has found. However, oseltamivir treatment leads to better recovery and shorter hospitalization in children with severe influenza A.

Treatment with the antisense oligonucleotide bepirovirsen appears to lead to sustained loss of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA in up to 10 percent of patients with chronic HBV infection, according to the results of the phase IIb study B-Clear.

Paediatric patients with acute myeloid leukaemia and other leukaemias (AML/OLs), especially those with persistent neutropaenia during the first 30 postoperative days, are at increased risk of early catheter-related bloodstream infections (CRBSIs), according to a Singapore study.

Children in Singapore are at risk of developing multisystem inflammatory syndrome (MIS-C), especially due to the increased community transmission of COVID-19 in 2021, according to a study. MIS-C incidence may also intensify with the arrival of new variants of concern (VOCs) and relaxation of pandemic restrictions.

A procalcitonin-guided algorithm could reduce the unnecessary use of antibiotics in patients with acute pancreatitis, according to results of the PROCAP trial.

The serine protease inhibitor upamostat appears to be beneficial in the treatment of COVID-19 outpatients, being generally tolerable and bringing a rapid resolution of severe symptoms while reducing the incidence of new ones, according to the results of a pilot study.

Weekly bepirovirsen treatment may help reduce HBsAg* and hepatitis B virus (HBV) DNA levels in patients with chronic HBV infection, the phase IIb B-Clear study showed.

One in every eight individuals who has experienced COVID-19 may have persistent symptoms 3–5 months post-infection, according to an observational study from the Netherlands.